Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Dipeptidyl peptidase 4 (DPP4) and α-glucosidase inhibitors have been developed as anti-diabetic agents for the treatment of diabetes mellitus. In the present study, the anti-diabetic effects of the lupinalbin A compound isolated from was investigated by measuring its inhibitory activity against DPP4 and α-glucosidase. To detect the inhibitory effect of lupinalbin A, DPP4 and α-glucosidase assays were performed . Molecular docking analysis was performed using AutoDock 4.2. The IC values of lupinalbin A against DPP4 and α-glucosidase were 45.2 and 53.4 µM, respectively. Analysis of the enzyme kinetics revealed that lupinalbin A interacted with the active site of DPP4 in a competitive manner, with an inhibition constant () value of 35.1±2.0 µM, whereas the lupinalbin A interaction with α-glucosidase was non-competitive, with a value of 45.0 µM. Molecular docking analysis revealed a binding pose between the DPP4 enzyme and lupinalbin A. Taken together, these data suggest lupinalbin A is more effective against DPP4 than α-glucosidase, with regard to its anti-diabetic effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938295 | PMC |
| http://dx.doi.org/10.3892/br.2021.1415 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.
JAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.
Effect of the DPP4 Inhibitor Sitagliptin on Ferroptosis in Epilepsy.
J Integr Neurosci
August 2025
Central Laboratory, The First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People's Hospital), 454001 Jiaozuo, Henan, China.
Background: Epilepsy, a significant neurological condition marked by the occurrence of repeated seizures, continues to pose a substantial health challenge. Previous studies have indicated that Dipeptidyl Peptidase-4 (DPP4) inhibitors may possess antiepileptic properties. Ferroptosis, a newly discovered type of programmed cell death, has recently surfaced as a promising therapeutic target in the management of epilepsy.
View Article and Find Full Text PDFFrom Glucose to Gauze: A Systematic Review on the Various Wound Healing Properties of DPP-4 Inhibitors Beyond Glycaemic Control.
Wound Repair Regen
September 2025
Center for Tissue Engineering, Department of Plastic Surgery, University of California Irvine, Orange, California, USA.
Dipeptidyl-peptidase 4 inhibitors, DPP-4i, are an established antiglycaemic medication for Type 2 Diabetes. There has been a growing interest in DPP-4i's potential to improve wound healing and reduce fibrosis. The purpose of this study is to survey the current literature for applications of DPP-4i in wound healing and scars, and explore their potential outside of glycaemic control.
View Article and Find Full Text PDFElectronic Health Record (EHR) Enhanced Signal Detection Using Tree-Based Scan Statistic Methods.
Am J Epidemiol
September 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tree-based scan statistics (TBSS) are data mining methods that screen thousands of hierarchically related health outcomes to detect unsuspected adverse drug effects. TBSS traditionally analyze claims data with outcomes defined via diagnosis codes. TBSS have not been previously applied to rich clinical information in Electronic Health Records (EHR).
View Article and Find Full Text PDFMulti-omics and experimental validation reveal the mechanism of DanxiaTiaoban decoction in treating atherosclerosis.
Phytomedicine
August 2025
Cardiology Department, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. Electronic address:
Background: Atherosclerosis (AS) is a leading risk factor for cardiovascular diseases globally, characterised by the accumulation of lipids and cholesterol in arterial walls, causing vascular narrowing and sclerosis along with chronic inflammation; this leads to increased risk of heart disease and stroke, significantly impacting patients' health. Danxia Tiaoban Decoction (DXTB), a traditional Chinese medicine (TCM) formula, has demonstrated positive clinical effects in treating AS; however, its mechanisms of action remain unclear.
Objective: To explore the potential mechanisms of action of DXTB in treating AS through multi-omics integration and experimental validation.